Mara Rabin, MD
Family Medicine · Salt Lake City, UTNPI 1225161003
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 55.8% of the total. That places this record below the midpoint for family medicine clinicians in UT, where the typical reported total is $341.
Across 18 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$209
- Dexcom, Inc.$41
- Exact Sciences$21
- Boehringer Ingelheim$19
- Novo Nordisk$19
- Actelion Pharmaceuticals US, Inc.$18
- plus $47 from 3 others
Across 172 payments — averaging $6311.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$249K
- Organon$225K
- Mylan Inc.$157K
- Sumitomo Pharma America, Inc.$129K
- Mylan Technologies Inc.$125K
- Eli Lilly$82K
- plus $117K from 5 others
What the payments were for
- Food & beverage$374100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $209 |
| Dexcom, Inc. | 2 | $41 |
| Exact Sciences | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Boston Scientific | 1 | $16 |
| GSK | 1 | $15 |
How this compares
$374 in reported general payments places this provider in the 50th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 39 | $37,875 |
| RybelsusSemaglutide | 11 | $12,455 |
| Levothyroxine Sodium | 96 | $763 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $655 |
| Bupropion XlBupropion Hcl | 21 | $610 |
| Amlodipine Besylate | 75 | $591 |
| Losartan Potassium | 64 | $574 |
| Atorvastatin Calcium | 61 | $492 |
| Simvastatin | 67 | $431 |
| Metoprolol Succinate | 13 | $368 |
| Ezetimibe | 14 | $341 |
| ValacyclovirValacyclovir Hcl | 15 | $340 |
| Metformin Hcl | 13 | $294 |
| Escitalopram Oxalate | 22 | $255 |
| Fluticasone Propionate | 18 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $19 | $12,45511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 928 family medicine providers in Utah.
Other family medicine in Salt Lake City
- Mark CacciamaniSalt Lake City$43K
- Kirk OdonnellSalt Lake City$23K
- Jared ProbstSalt Lake City$15K
- Derek MuseSalt Lake City$14K
- Kristen RomoSalt Lake City$13K
- Julie DaySalt Lake City$11K
- Mark JohnsonSalt Lake City$8K
- Stephen ColemanSalt Lake City$8K
- David LarsenSalt Lake City$8K
- Michael CobbleSandy$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.